QQQ   302.94 (-0.17%)
AAPL   122.91 (+0.15%)
MSFT   214.21 (-0.93%)
FB   287.58 (+0.36%)
GOOGL   1,824.04 (+1.60%)
AMZN   3,204.20 (-0.49%)
TSLA   557.95 (-4.58%)
NVDA   541.20 (+1.05%)
BABA   261.78 (-0.84%)
CGC   28.35 (+6.38%)
GE   10.35 (+1.97%)
MU   68.63 (+2.31%)
AMD   93.55 (+0.99%)
T   28.93 (+0.21%)
NIO   47.40 (+4.50%)
F   9.17 (-0.76%)
ACB   10.91 (+11.90%)
NFLX   502.51 (-0.41%)
BA   221.64 (+4.05%)
GILD   61.15 (+0.05%)
DIS   152.39 (+1.97%)
QQQ   302.94 (-0.17%)
AAPL   122.91 (+0.15%)
MSFT   214.21 (-0.93%)
FB   287.58 (+0.36%)
GOOGL   1,824.04 (+1.60%)
AMZN   3,204.20 (-0.49%)
TSLA   557.95 (-4.58%)
NVDA   541.20 (+1.05%)
BABA   261.78 (-0.84%)
CGC   28.35 (+6.38%)
GE   10.35 (+1.97%)
MU   68.63 (+2.31%)
AMD   93.55 (+0.99%)
T   28.93 (+0.21%)
NIO   47.40 (+4.50%)
F   9.17 (-0.76%)
ACB   10.91 (+11.90%)
NFLX   502.51 (-0.41%)
BA   221.64 (+4.05%)
GILD   61.15 (+0.05%)
DIS   152.39 (+1.97%)
QQQ   302.94 (-0.17%)
AAPL   122.91 (+0.15%)
MSFT   214.21 (-0.93%)
FB   287.58 (+0.36%)
GOOGL   1,824.04 (+1.60%)
AMZN   3,204.20 (-0.49%)
TSLA   557.95 (-4.58%)
NVDA   541.20 (+1.05%)
BABA   261.78 (-0.84%)
CGC   28.35 (+6.38%)
GE   10.35 (+1.97%)
MU   68.63 (+2.31%)
AMD   93.55 (+0.99%)
T   28.93 (+0.21%)
NIO   47.40 (+4.50%)
F   9.17 (-0.76%)
ACB   10.91 (+11.90%)
NFLX   502.51 (-0.41%)
BA   221.64 (+4.05%)
GILD   61.15 (+0.05%)
DIS   152.39 (+1.97%)
QQQ   302.94 (-0.17%)
AAPL   122.91 (+0.15%)
MSFT   214.21 (-0.93%)
FB   287.58 (+0.36%)
GOOGL   1,824.04 (+1.60%)
AMZN   3,204.20 (-0.49%)
TSLA   557.95 (-4.58%)
NVDA   541.20 (+1.05%)
BABA   261.78 (-0.84%)
CGC   28.35 (+6.38%)
GE   10.35 (+1.97%)
MU   68.63 (+2.31%)
AMD   93.55 (+0.99%)
T   28.93 (+0.21%)
NIO   47.40 (+4.50%)
F   9.17 (-0.76%)
ACB   10.91 (+11.90%)
NFLX   502.51 (-0.41%)
BA   221.64 (+4.05%)
GILD   61.15 (+0.05%)
DIS   152.39 (+1.97%)
Log in
ARCA:PLX

Protalix BioTherapeutics Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume77,394 shs
Market Capitalization$118.09 million
P/E RatioN/A
Dividend YieldN/A
Beta2.8
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. was founded in 1993 and is headquartered in Karmiel, Israel.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.13 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone972 4 988 9488
Employees196

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$54.69 million
Book Value($4.74) per share

Profitability

Net Income$-18,280,000.00

Miscellaneous

Market Cap$118.09 million
Next Earnings DateN/A
OptionableOptionable
30 days | 90 days | 365 days | Advanced Chart

Receive PLX News and Ratings via Email

Sign-up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Protalix BioTherapeutics (ARCA:PLX) Frequently Asked Questions

What stocks does MarketBeat like better than Protalix BioTherapeutics?

Wall Street analysts have given Protalix BioTherapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Protalix BioTherapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Protalix BioTherapeutics' key competitors?

Who are Protalix BioTherapeutics' key executives?

Protalix BioTherapeutics' management team includes the following people:
  • Mr. Dror Bashan, Pres, CEO & Director (Age 53, Pay $404.53k)
  • Mr. Eyal Rubin M.B.A., Sr. VP, CFO, Treasurer & Corp. Sec. (Age 44, Pay $323.63k)
  • Mr. Yaron Naos, Sr. VP of Operations (Age 56, Pay $305.87k)
  • Dr. Einat Brill-Almon, Sr. VP & Chief Devel. Officer (Age 60, Pay $328.26k)
  • Ms. Dafna Shelly M.Sc., MBA, VP of HR

What is Protalix BioTherapeutics' stock symbol?

Protalix BioTherapeutics trades on the ARCA under the ticker symbol "PLX."

How do I buy shares of Protalix BioTherapeutics?

Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Protalix BioTherapeutics?

Protalix BioTherapeutics has a market capitalization of $0.00 and generates $54.69 million in revenue each year. The company earns $-18,280,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Protalix BioTherapeutics employs 196 workers across the globe.

What is Protalix BioTherapeutics' official website?

The official website for Protalix BioTherapeutics is www.protalix.com.

How can I contact Protalix BioTherapeutics?

The company can be reached via phone at 972 4 988 9488.

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.